Decision model reveals trade-offs among device durability, efficacy, and cost in device-treated patients, highlighting the need for rigorous value assessment beyond precursor similarity.
The FDA approves many devices on the basis of similarity to precursors, possibly encouraging development of slightly improved, higher-cost devices. A modeling approach can illuminate interplay among efficacy and durability, patient characteristics, costs, and outcomes.
No takes yet. Share an insight, caveat, or question.
Suter et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: